Researchers at the Ribeirão Preto Blood Center and the University of São Paulo’s Center for Cell‑Based Therapy reported novel approaches that enhance CAR‑NK efficacy using the NK‑92 cell line. The team described engineering and combinatorial strategies that improve persistence, limit exhaustion, and increase anti‑tumor activity in preclinical models, providing data at a recent conference that support further development toward clinical translation. The work focuses on practical improvements in NK cell potency and manufacturability, including construct design and tumor‑microenvironment modulation. Investigators noted NK‑92 offers an off‑the‑shelf platform for CAR‑NK therapies, but emphasized the need for clinical studies to confirm safety and durability.